2m 2m 2m 2m 2m 2m 2m
Voyager Therapeu (VYGR)
NASDAQ
$3.55-$0.05 (-1.39%)
Price as of Jun 03, 2026 6:47 PM EDT- $233.8MMarket Cap
- 8.43%1-Year Change
- BiotechnologyIndustry
Voyager Therapeu (VYGR)
$3.55-$0.05 (-1.39%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 40.4M -49.53% | 80.0M -68.00% | 250.0M +511.16% | 40.9M +9.33% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 40.4M -49.53% | 80.0M -68.00% | 250.0M +511.16% | 40.9M +9.33% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -134.7M +5.74% | -127.4M +38.19% | -92.2M +51.69% | -60.8M -17.65% | |
Depreciation and Amortization Expense | 4.1M -14.18% | 4.7M +6.53% | 4.4M -28.27% | 6.2M +19.86% | |
Total Operating Expenses | 172.2M +5.47% | 163.3M +27.57% | 128.0M +39.51% | 91.7M -17.37% | |
Operating Profit | -131.8M +58.30% | -83.3M -168.26% | 122.0M +340.01% | -50.8M -30.94% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 12.3M -35.27% | 18.9M +61.63% | 11.7M +163.76% | 4.4M +83.60% | |
Income before Taxes | -119.6M +85.86% | -64.3M -148.11% | 133.7M +388.28% | -46.4M -36.98% | |
Income Taxes | 144,000 -78.35% | 665,000 -52.77% | 1.4M +8,700.00% | 16,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -119.7M +84.18% | -65.0M -149.12% | 132.3M +385.14% | -46.4M -34.82% | |
Net Income from Continuing Operations Applicable to Common | -119.6M +85.86% | -64.3M -148.11% | 133.7M +388.28% | -46.4M -34.84% | |
Basic EPS and Net Income | -2.04 +80.53% | -1.13 -136.69% | 3.08 +354.55% | -1.21 -35.98% | |
Diluted EPS and Net Income | -2.04 +80.53% | -1.13 -138.05% | 2.97 +345.45% | -1.21 -35.98% | |
Basic Weighted Average Shares | 58.7M +1.77% | 57.7M +34.05% | 43.0M +12.16% | 38.4M +1.83% | |
Diluted Weighted Average Shares | 58.7M +1.77% | 57.7M +29.39% | 44.6M +16.20% | 38.4M +1.83% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 65.3M -8.50% | 71.4M +3.73% | 68.8M -30.47% | 99.0M -15.73% | |
Short-Term Investments | 131.1M -32.85% | 195.3M +20.51% | 162.1M +714.89% | 19.9M +31.66% | |
Cash and Cash Equivalents and Short-Term Investments | 196.4M -26.34% | 266.7M +15.51% | 230.9M +94.26% | 118.8M -10.33% | |
Total Current Assets | 202.7M -26.78% | 276.8M -13.41% | 319.7M +156.78% | 124.5M -8.92% | |
Accumulated Depreciation | 19.2M +20.01% | 16.0M +6.12% | 15.0M -12.61% | 17.2M +8.13% | |
Property and Plant and Equipment and Net | 13.1M -8.23% | 14.3M -13.22% | 16.5M -7.63% | 17.9M -18.54% | |
Total Long-Term Assets | 18.4M -77.03% | 80.0M +385.13% | 16.5M -7.63% | 17.9M -18.54% | |
Total Assets | 252.3M -35.81% | 393.1M +11.89% | 351.3M +120.44% | 159.4M -17.80% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 26.5M -46.69% | 49.8M -22.82% | 64.5M -11.13% | 72.6M +42.39% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 34.7M -18.45% | 42.5M +134.90% | 18.1M -15.03% | 21.3M -46.24% | |
Total Liabilities | 56.2M -39.76% | 93.3M -18.85% | 115.0M +14.58% | 100.3M +1.55% | |
Retained Earnings | -445.9M +36.70% | -326.2M +24.89% | -261.2M -33.63% | -393.5M +13.37% | |
Total Stockholders Equity | 196.1M -34.59% | 299.8M +26.84% | 236.3M +300.41% | 59.0M -37.91% | |
Total Shares Outstanding | 59.0M +7.89% | 54.7M +24.28% | 44.0M +14.05% | 38.6M +1.83% | |
Cash Flow | |||||
Cash from Operating Activities | -132.5M +765.23% | -15.3M -119.65% | 77.9M +722.90% | -12.5M -76.63% | |
Capital Expenditures | 2.6M -26.27% | 3.5M +8.14% | 3.3M +30.71% | 2.5M +54.82% | |
Cash from Investing Activities | 125.4M +232.24% | -94.9M -33.03% | -141.6M +1,830.00% | -7.3M -111.14% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 816,000 -99.28% | 114.0M +238.88% | 33.6M +2,931.08% | 1.1M +81.37% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -326.56% +213.67% | -104.11% -313.32% | 48.80% +139.27% | -124.27% -36.84% | |
Return on Assets | -37.10% +112.44% | -17.47% -133.70% | 51.83% +297.24% | -26.28% -15.95% | |
Return on Equity | -48.29% +99.13% | -24.25% -127.06% | 89.61% +248.76% | -60.24% +5.50% | |
Revenue Growth | -49.53% -27.16% | -68.00% -113.30% | 511.16% +5,376.81% | 9.33% +111.94% | |
Current Ratio | 7.64 +37.36% | 5.56 +12.19% | 4.96 +188.95% | 1.72 -36.04% | |
Cash Ratio | 2.46 +71.64% | 1.43 +34.39% | 1.07 -21.76% | 1.36 -40.82% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow